POSITRON Business Summary

Positron Corp (POSC) is a specialized medical technology company that develops, manufactures, and services high-performance Positron Emission Tomography (PET) and PET-CT molecular imaging systems, primarily targeting the nuclear cardiology and oncology markets. The company generates revenue through a multi-tiered model comprising the direct sale of imaging hardware—notably its Attrius PET and NeuSight PET-CT 64-slice systems—alongside long-term service contracts, clinical training, and technical support. To lower the barrier to entry for private practices and community hospitals, Positron utilizes flexible financial models, including rental and lease-to-own programs. The firm operates through two primary segments: Medical Equipment and Radiopharmaceuticals/Clinical Services, recently expanding its portfolio with the Affinity PET-CT 4D system. Within the competitive landscape, Positron contends with industry giants such as GE HealthCare, Siemens Healthineers, and Philips; however, it differentiates itself as a cost-effective, niche provider that offers specialized cardiac diagnostic capabilities and a smaller equipment footprint tailored for outpatient clinical environments. Originally founded in 1983 by Roman Oliynyk, Positron is currently led by Adel Abdullah, who serves as President, CEO, and Chairman of the Board. Abdullah, who has been with the company for over 15 years, is credited with steering the firm through its 2025 transition to an SEC-reporting company and securing strategic co-development partnerships with Neusoft Medical Systems. The executive team includes Aaron Hargrave as Vice President of Clinical Applications, Bernie Sardinha as Chief Operating Officer, and Co-Founder Edward Kmett, who serves as Chief Scientist. The company’s governance is supported by an experienced board of directors, including independent members Tis Prager, Sachio Okamura, and Anthony Nicholls. Notable ownership is concentrated among individual insiders, with George Ortiz and Tis Prager holding significant equity stakes, while recent capital infusions, including a $2 million raise in early 2026, have been directed toward accelerating the commercialization of next-generation 4D imaging technologies.